4 Podcast Episodes
Optimizing Cardiovascular Outcomes in Type 2 Diabetes: Beyond A1C Goals - Susan Cornell, PharmD and Randolph V. Fugit, PharmD
Optimizing Cardiovascular Outcomes in Type 2 Diabetes: Beyond A1C Goals - Susan Cornell, PharmD and Randolph V. Fugit, PharmD
Recorded during the AHSP Midyear Meeting, this webcast discusses translating outcomes from T2DM cardiovascular trials in... Read more
17 Dec 2019
•
1hr 29mins
Optimizing Cardiovascular Outcomes in Type 2 Diabetes: Beyond A1C Goals - Susan Cornell, PharmD and Randolph V. Fugit, PharmD
Optimizing Cardiovascular Outcomes in Type 2 Diabetes: Beyond A1C Goals - Susan Cornell, PharmD and Randolph V. Fugit, PharmD
Recorded during the AHSP Midyear Meeting, this webcast discusses translating outcomes from T2DM cardiovascular trials in... Read more
17 Dec 2019
•
1hr 29mins
Novel DOAC Reversal Strategies: Update on Best Practices - Mark A. Munger, PharmD, FCCP, FACC, FHFSA, Randolph V. Fugit, PharmD, BCPS, and Paul P. Dobesh, PharmD, FCCP, BCPS, BCCP
Novel DOAC Reversal Strategies: Update on Best Practices - Mark A. Munger, PharmD, FCCP, FACC, FHFSA, Randolph V. Fugit, PharmD, BCPS, and Paul P. Dobesh, PharmD, FCCP, BCPS, BCCP
Learn about the mechanisms of action and safety/efficacy data for currently-approved DOAC reversal agents, and gain insi... Read more
29 Apr 2019
•
1hr 1min
Novel DOAC Reversal Strategies: Update on Best Practices - Mark A. Munger, PharmD, FCCP, FACC, FHFSA, Randolph V. Fugit, PharmD, BCPS, and Paul P. Dobesh, PharmD, FCCP, BCPS, BCCP
Novel DOAC Reversal Strategies: Update on Best Practices - Mark A. Munger, PharmD, FCCP, FACC, FHFSA, Randolph V. Fugit, PharmD, BCPS, and Paul P. Dobesh, PharmD, FCCP, BCPS, BCCP
Learn about the mechanisms of action and safety/efficacy data for currently-approved DOAC reversal agents, and gain insi... Read more
29 Apr 2019
•
1hr 1min